Search Results

You are looking at 1 - 10 of 33 items for :

  • "intraperitoneal chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Point: Intraperitoneal Chemotherapy in the Management of Ovarian Cancer

Maurie Markman

intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy . Cancer Res 1989 : 49 : 3380 – 3384 . 10 Howell SB Pfeifle CE Wung WE . Intraperitoneal cisplatin with systemic thiosulfate protection . Ann

Full access

Counterpoint: Intraperitoneal Chemotherapy: An Investigational Treatment in Ovarian Cancer

Robert F. Ozols

cancer . Cancer Treat Rep 1978 ; 62 : 1 – 11 . 8 Markman M . Intraperitoneal chemotherapy . Semin Oncol 1991 ; 18 : 248 – 254 . 9 Markman M Reichman B Hakes T . Evidence supporting the superiority of intraperitoneal cisplatin

Full access

Intraperitoneal Chemotherapy for Ovarian Cancer: Where Are We Now?

Pankaj Singhal and Shashikant Lele

58 . 14. Kirmani S Braly PS McClay EF . A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer . Gynecol Oncol 1994 ; 54 : 338 – 344 . 15. Alberts DS Liu PY Hannigan EV

Full access

Current Concepts in the Evaluation and Treatment of Patients With Diffuse Malignant Peritoneal Mesothelioma

Keli Turner, Sheelu Varghese, and H. Richard Alexander

intraperitoneal chemotherapy (HIPEC), usually with mitomycin C or cisplatin, has been largely established as the best initial therapeutic intervention in selected patients with DMPM. The intent of operation with CRS and HIPEC is to remove all gross disease and

Full access

Ovarian Cancer, Version 2.2013

Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer, and Miranda Hughes

combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial . Lancet 2009 ; 374 : 1331 – 1338 . 20. Markman M Walker JL . Intraperitoneal chemotherapy of ovarian cancer: a review

Full access

New Issues in Systemic Therapy for Ovarian Cancer

Deborah K. Armstrong

confirmatory North American trial, Dr. Armstrong added. Intraperitoneal Chemotherapy Patients with low-volume disease (after optimal surgical debulking) benefit from intraperitoneal delivery of chemotherapy, but it increases toxicity and requires strong

Full access

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

postoperative therapy in patients who have received NACT and IDS ( supplemental eTable 3 ). Given the lack of survival improvement in OV21/PETROC, more data are needed to establish whether postoperative intraperitoneal chemotherapy provides clinical benefit in

Full access

Principles of Surgical Management of Peritoneal Mesothelioma

Jessica A. Steadman and Travis E. Grotz

, 2 Radical resection with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) remains the primary curative therapy for malignant peritoneal mesothelioma (MPeM), and the strongest predictor of long-term survival is

Full access

Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study

Mary Katherine Montes de Oca, Lauren E. Wilson, Rebecca A. Previs, Anjali Gupta, Ashwini Joshi, Bin Huang, Maria Pisu, Margaret Liang, Kevin C. Ward, Maria J. Schymura, Andrew Berchuck, and Tomi F. Akinyemiju

intraperitoneal chemotherapy; TAH, total abdominal hysterectomy. a NCCN Guidelines specifically recommend 3–6 cycles of intravenous platinum doublet. b NCCN Guidelines specifically recommend 6–8 cycles of intravenous platinum doublet. Adapted from Morgan RJ

Full access

HSR19-110: Predicting Candidates for Cytoreductive Surgery and HIPEC: The Role of Computed Tomography and Diagnostic Laparoscopy

Leigh Selesner, Gabrielle Gauvin, Dorotea Mutabdzic, Eileen O’Halloran, Maxwell Kilcoyne, Kwan-Keat Ang, Jeffrey Farma, Elin Sigurdson, and Sanjay Reddy

Introduction: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) has led to improved survival in select patients with peritoneal surface malignancies. Predicting the volume of disease and any unresectable disease is